SCHEMBL4941679

SCHEMBL4941679

CCNC(=O)c1cc(COS(C)(=O)=O)ccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.46
LOXL2 Q9Y4K0 1/20 0.43
CSF1R P07333 1/20 0.40
SMYD3 Q9H7B4 1/20 0.40
POLB P06746 1/20 0.40
BRAF P15056 2/20 0.39
KIT P10721 1/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RAF1 P04049 3/20 0.38
CYP4F2 P78329 2/20 0.38
CYP4A11 Q02928 2/20 0.38
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
ADORA1 P30542 1/20 0.36
CTSA P10619 2/20 0.36
DDR1 Q08345 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4307516 0.86 PARP1 (0.45) PARP1LOXL2CSF1RSMYD3KIT
SCHEMBL4937449 0.86 LOXL2 (0.46) LOXL2BRAFKITKDM4ELMNA
SCHEMBL12259341 0.82 PARP1 (0.48) PARP1LOXL2CSF1RSMYD3BRAF
SCHEMBL10204398 0.82 ALDH1A1 (0.45) PARP1SMYD3KDM4ELMNA
SCHEMBL1166333 0.82 ALDH1A1 (0.39) PARP1LOXL2SMYD3HTTCYP4F2
SCHEMBL4941722 0.81 SMYD3 (0.60) PARP1SMYD3BRAFKITADORA1
SCHEMBL4310539 0.81 CYP4F2 (0.46) LOXL2CSF1RSMYD3CYP4F2CYP4A11
SCHEMBL12233639 0.80 LOXL2 (0.47) PARP1LOXL2CSF1RSMYD3BRAF
SCHEMBL28728220 0.80 GABRA1 (0.43) KDM4ELMNAHSP90AA1SMN1; SMN2
SCHEMBL10283833 0.80 SMYD3 (0.57) PARP1LOXL2CSF1RSMYD3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293696-A1 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents BAYER PHARMACEUTICALS CORPORATION (US) 2008-11-27 US disclosed
US-20080293696-A1 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents BAYER PHARMACEUTICALS CORPORATION (US) 2008-11-27 US disclosed
US-20080293696-A1 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents BAYER PHARMACEUTICALS CORPORATION (US) 2008-11-27 US disclosed
EP-1765811-A2 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS Bayer Pharmaceuticals Corporation (US) 2007-03-28 EP disclosed
WO-2006023707-A2 2-AMINOTHIOPHENECARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS BAYER PHARMACEUTICALS CORPORATION (US) 2006-03-02 WO disclosed
WO-2006002383-A2 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS BAYER PHARMACEUTICALS CORPORATION (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293696-A1 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents ABCC3, HCCS, ABCC2 PARP1 834/4885LOXL2 4559/4885CSF1R 2802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.